Lidocaine Injection Versus Sham Needling in Treating Whiplash Associated Disorder

Sponsor
Hamilton Health Sciences Corporation (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02060734
Collaborator
(none)
0
2
2
11
0
0

Study Details

Study Description

Brief Summary

To determine the efficacy of lidocaine injection of trigger points versus subcutaneous injection in patients with subacute whiplash associated disorder following injury.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Lidocaine
  • Other: Saline
Phase 4

Detailed Description

This is a double-blind, randomized controlled trial to determine the efficacy of lidocaine injection of trigger points versus subcutaneous injection in patients with subacute whiplash associated disorder following injury. Outcomes include pain, objective assessment, self-report function recovery, impact on work performance and globe perceived effects which will be assessed 5 minutes, 2 and 6 weeks following injection.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Lidocaine Injection Versus Sham Needling in Treating Whiplash Associated disorder-a Randomized Controlled Trial
Study Start Date :
Oct 1, 2015
Anticipated Primary Completion Date :
Jan 1, 2016
Anticipated Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: lidocaine

The treatment group will receive a 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point. Three to five points injection.

Procedure: Lidocaine
Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).

Active Comparator: Saline

The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.

Other: Saline
The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.

Outcome Measures

Primary Outcome Measures

  1. pain [2 weeks following injection]

    10 cm Visual Analog Scale

Secondary Outcome Measures

  1. cervical range of motion [Immediately, 2 and 6 weeks after injection]

  2. self-report neck disability [Immediately, 2 and 6 weeks after injection]

  3. globe perceived effects [Immediately, 2 and 6 weeks after injection]

    The Short Form-12

  4. work performance [Immediately, 2 and 6 weeks after injection]

    questionnaire

  5. pain [5 minutes following injection]

    10 cm Visual Analog Scale

  6. pain [6 weeks following injection]

    10 cm Visual Analog Scale

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • fulfill the Grade II Quebec Task Force classification of WAD,

  • with identifiable myofascial trigger points ( which occur with or without a taut band),

  • reproduction of recognizable pain with sustained pressure ( up to 10 seconds) on trigger points

  • aged 18 to 70

  • a good understanding of informed consent and willing to attend this trial.

Exclusion Criteria:
  • have serious injury such as fracture and internal bleeding

  • suspicion of upper cervical instability or neurological deficits

  • clinical evidence of radiculopathy

  • a history of active cancer, central nerve disorder, blood clotting disorders, needle phobia

  • anticoagulant medication user

  • previous experience with any type of needling for myofascial pain

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of physical medicine and rehabilitation, McMaster University Hamilton Ontario Canada L8V 1C3
2 HHS (Juravinski Hospital Site) Hamilton Ontario Canada L8V 1C3

Sponsors and Collaborators

  • Hamilton Health Sciences Corporation

Investigators

  • Study Director: Joy MacDermid, Ph.D., McMaster University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maggie Qiyun Shi, Graduate student, Western University, Hamilton Health Sciences Corporation
ClinicalTrials.gov Identifier:
NCT02060734
Other Study ID Numbers:
  • HHSCTRIGGERINJ1402
First Posted:
Feb 12, 2014
Last Update Posted:
Feb 23, 2017
Last Verified:
Aug 1, 2015
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Maggie Qiyun Shi, Graduate student, Western University, Hamilton Health Sciences Corporation
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2017